This study proposes a neural network-based technology opportunity analysis of patent data.

First, based on learning of the content characteristics of the data by deep learning algorithm, the extraction keyword model was formed. Content similarity between keywords was calculated based on the contents. Second, patent technology network was built based on the keywords. The link prediction algorithm was used to calculate the topology features of the network, including similarity features based on local information, random walk and path. Finally, the three types of network topology features and content features were input to the BP neural network model to predict potential technology opportunities.

The field of biological nanomedicine was selected as the empirical field. The top 10 technological opportunities with the highest probability score in the patented technology network were identified in the field of biomedicine.

The results were analyzed and evaluated through the literature retrospective method, and the latest literature found the research results on these technical opportunities, but they have not successfully applied for patents.

To establish the quality standard of Xianqian Granules.

According to the relevant methods presented in the fourth general rules of Pharmacopoeia of the People's Republic of China (2020), TLC method for identifying 4 Chinese medicinal materials in Xianqian Granules, including Agrimoniae Herba, Rubiae Radix et Rhizoma, Paeoniae Radix Rubra, and Notoginseng Radix et Rhizoma, was established, as well as the HPLC method for determining the index components of purpurin and paeoniflorin in Xianqian Granules.

The TLC method was specific to identify the 4 medicinal materials effectively. In the quantitative analysis method, the mass concentrations of purpurin and paeoniflorin were linear in the ranges of 2.47~53.00 μg·mL^-1 and 18.29~392.0 μg·mL^-1, respectively. The average recoveries were 97.37% (RSD 1.44%) and 99.04% (RSD 0.82%), respectively.

The established methods for quality evaluation of Xianqian Granules are simple, accurate, and specific, which can be used for the quality control for Xianqian Granules.

To explore the construction of clinical trial information management system and its practice in the process management of traditional Chinese medicine clinical trials, so as to improve the management efficiency of drug clinical trials.

In cooperation with Tianjin Abensu Science and Technology Co., Ltd., an information management platform for clinical trial institutions was constructed in the Affiliated Hospital of Chengdu University of traditional Chinese medicine. Through the intranet system, the hospital's original closed systems such as HIS, LIS and RIS were connected. After encrypted transmission, it completed data exchange and docking with the information system running on the internet. The electronic informatization of user management, project management, subject information management, process information management and experimental drug management of clinical trial realized. The security, stability and efficiency of the involved data were analyzed.

The system realized the safety, stability and smooth flow of data in the process of clinical trial management, and greatly improved the efficiency of traditional Chinese medicine (TCM) clinical trial project management.

The introduction of information management system and its integration with internal systems like HIS and LIS is the road which must be taken to realize the modern management of TCM clinical trial institutions, and it is one of the most important ways to practice the innovation of TCM.

To observe the protective effect of 6-O-methyl-catalpol on fructose-induced NAFLD in mice and its mechanism.

The mice were randomly divided into the control group and fructose-fed groups. After 4 weeks, the fructose-fed mice were further divided to 4 subgroups: model group, silybin group (35 mg·kg^-1), 6-O-methyl-catalpol (30 mg·kg^-1) group, and 6-O-methyl-catalpol (60 mg·kg^-1) group. The drugs were administered by gavage qd for a period of 4 weeks. At the end of the treatment, the levels of ALT, AST, TC, TG, GLU, insulin and leptin were determined. The histopathological changes of liver were evaluated using HE staining. The fatty acid synthetase (FAS) and acetyl CoA carboxylase (ACC) protein expression in liver were measured using Western blot.

Compare with the model group, the elevated levels of AST, ALT, TC, TG, insulin, leptin and HOMA-IR significantly decreased in 6-O-methyl-catalpol groups (P<0.01). HE staining showed that the degree of hepatic steatosis was obviously ameliorated in 6-O-methyl-catalpol treatment groups. The protein expression levels of ACC and FAS were also significantly down-regulated in high 6-O-methyl-catalpol group (P<0.01).

6-O-methyl-catalpol exerts protective effect against NAFLD, which may be related to the improvement of insulin sensitivity and lipid metabolism.

To explore the safety and efficacy of Inetetamab combined with Pyrotinib in the treatment of HER2-positive breast cancer.

A case of patient was reported with right breast invasive ductal carcinoma with multiple systemic metastases. The patients were found progressing after 3 cycles of docetaxel+Capecitabine+Trastuzumab regimen as the first line therapy for Trastuzumab primary resistance. Second-line therapy combined inetetamab with pyrotinib (inetetamab 8 mg·kg^-1 for the first time, followed by 6 mg·kg^-1, q3w+pyrotinib 400 mg·d^-1, qd+vinorelbine 35 mg day 1, day 8 q3w) for 18 cycles.

The patients achieved partial response (PR) at the first evaluation. During the 18 cycles of treatment, the efficacy was evaluated as continuous PR. The current progress free survival (PFS) was more than 16 months. No grade III or above adverse reactions occurred during the treatment, and the patients were well tolerated.

The combination of inetetamab with pyrotinib is effective and safe in the treatment of metastatic HER2-positive breast cancer.